PrecisionLife: Expanding Precision Medicine Beyond Oncology
What is one unique thing people should know about PrecisionLife that is not on your website?
PrecisionLife has negotiated access to over 60 datasets providing us with approximately 7 million individuals' genotype, genomic or multiomic data to power our studies. We collaborate globally with national scale biobanks, patient charities, healthcare systems, commercial biobanks and academic consortia.
Why did you choose to build in Oxfordshire? What is your connection to Oxford/Oxfordshire?
Two of our three founders met over 30 years ago at Oxford Molecular Group, one of the OUI's early spin outs, commercializing leading computational biology and chemistry software. They were keen to return to Oxford to build PrecisionLife.
What big problem are you trying to solve, and why does it matter?
We are expanding precision medicine beyond oncology to predict, treat and prevent complex chronic disease. These are the conditions that account for 80% of healthcare costs, and shorten all our lives.
How can you support — or be supported by — the Oxfordshire ecosystem?
We collaborate with academic groups in Oxfordshire to validate our novel insights. We also show up to support entrepreneurs, service providers and leaders who are organizing the Oxford ecosystem.